Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2012

View Archived Issues

Fifth phase III study of QVA-149 meets primary endpoint

New Afinitor formulation approved in U.S.

Creabilis products show promise as topical analgesics

PAR1 receptor antagonist prevents heart failure-induced atrial remodeling

Topical cream improves female sexual arousal disorder in phase III trial

Research at Kyowa Hakko Kirin produces new calcium channel antagonists

Merck KGaA patents novel protein kinase inhibitors

Novel inhibitors of JAK3 presented

New heat shock protein inhibitors designed in Japan

Lead product for Parkinson's disease advances through preclinical studies

Zinc peptidase implicated in ACS pathogenesis

Humira indication broadened in Europe

Enrollment complete in phase Ib trial of CALAA-01

ARIAD submits MAA to EMA

PharmaMar product gets orphan drug designation

Exelixis provides update on FDA meeting for cabozantinib

Infradure tissue implant cleared for two hepatitis C trials in Israel

Genmab and Janssen Biotech form worldwide agreement

New drug approved for IBS-C and CIC

Sunovion signs definitive acquisition agreement

FDA grants orphan drug designation to ARLN-05

Lead Nordic Nanovector product clear to enter clinic

Bayer HealthCare submits NDA for regorafenib

New genetic test predicts response to antipsychotics/antidepressants

PR-610 enters phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.